Stryker Corp. announced on May 2 that it completed its acquisition of Cerus Endovascular Ltd. According to data captured in the LevinPro HC database, this represents the 41st Medical Devices transaction of the year.
Cerus Endovascular is a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms.
Stryker develops, manufactures and markets specialty surgical and medical products. These include orthopedic implants, powered surgical instruments, endoscopic systems and patient care and handling equipment. Stryker impacts more than 130 million patients annually. Stryker’s revenue for the 12 months ending December 31, 2022 was $18.449 billion.
Cerus Endovascular’s CE Marked products, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, will expand Stryker’s current portfolio of aneurysm treatment solutions. Technology for the endovascular treatment of aneurysms has been foundational to Stryker’s Neurovascular division and Cerus Endovascular’s portfolio will address the growing need for one-and-done intrasaccular aneurysm therapy.
